Company intelligence / Profile preview

AnaCardio

Ownership: Private
Development stage: Phase 1

Overview

AnaCardio is developing novel inotropic agents that increase cardiac output without causing adverse effects like tachycardia, arrhythmia, ischemia, or hypotension. Their lead program AC01 entered phase 1b/2a clinical development in heart failure patients in 2023[7]. The company recently received a patent grant in Europe for AC01 in March 2025[1].

Therapeutic areas: Cardiovascular
Modalities: Novel inotropic agents
Industry: Biotech

Drug pipeline

1 asset

AC01

Beyond the preview

Go deeper on AnaCardio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnaCardio.

Explore the full profile